Northern Trust Corp Purchases Shares of 204,519 Strongbridge Biopharma plc (SBBP)

Northern Trust Corp purchased a new stake in Strongbridge Biopharma plc (NASDAQ:SBBP) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 204,519 shares of the biotechnology company’s stock, valued at approximately $1,462,000. Northern Trust Corp owned 0.58% of Strongbridge Biopharma as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Schwab Charles Investment Management Inc. acquired a new position in Strongbridge Biopharma during the 2nd quarter valued at about $332,000. Rhumbline Advisers acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $154,000. State of Wisconsin Investment Board acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $114,000. Bank of New York Mellon Corp acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $331,000. Finally, Teachers Advisors LLC acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter worth approximately $297,000. 57.53% of the stock is owned by institutional investors and hedge funds.

Shares of Strongbridge Biopharma plc (NASDAQ SBBP) opened at $6.30 on Tuesday. The company has a current ratio of 4.70, a quick ratio of 4.61 and a debt-to-equity ratio of -1.89. Strongbridge Biopharma plc has a fifty-two week low of $2.00 and a fifty-two week high of $8.85.

A number of brokerages have recently weighed in on SBBP. Oppenheimer began coverage on shares of Strongbridge Biopharma in a research note on Thursday, August 10th. They issued an “outperform” rating and a $12.00 price target for the company. Zacks Investment Research upgraded shares of Strongbridge Biopharma from a “sell” rating to a “hold” rating and set a $7.25 target price on the stock in a report on Wednesday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Strongbridge Biopharma in a report on Wednesday, November 15th. Finally, ValuEngine downgraded shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Strongbridge Biopharma has a consensus rating of “Hold” and a consensus target price of $11.81.

COPYRIGHT VIOLATION NOTICE: “Northern Trust Corp Purchases Shares of 204,519 Strongbridge Biopharma plc (SBBP)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/05/northern-trust-corp-purchases-shares-of-204519-strongbridge-biopharma-plc-sbbp.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Institutional Ownership by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

What are top analysts saying about Strongbridge Biopharma plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Strongbridge Biopharma plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit